Match!
Jonathan A. Ledermann
University College London
PathologyOncologyChemotherapyOvarian cancerMedicine
342Publications
49H-index
13.1kCitations
What is this?
Publications 348
Newest
#1Sarah P. Blagden (University of Oxford)H-Index: 12
#2Adrian Cook (UCL: University College London)H-Index: 14
Last. Elizabeth C. James (UCL: University College London)H-Index: 2
view all 19 authors...
Summary Background The ICON8 study reported no significant improvement in progression-free survival (a primary endpoint) with weekly chemotherapy compared with standard 3-weekly treatment among patients with epithelial ovarian cancer. All ICON8 patients were eligible to take part in the accompanying health-related quality-of-life study, which measured the effect of treatment on self-reported wellbeing, reported here. Methods In this open-label, randomised, controlled, phase 3, three-arm, Gynecol...
1 CitationsSource
#1Andres PovedaH-Index: 32
#2Anne FloquetH-Index: 29
Last. Michael Friedlander (UNSW: University of New South Wales)H-Index: 64
view all 19 authors...
Source
#2Chee Khoon Lee (USYD: University of Sydney)H-Index: 21
Last. Tomasz Huzarski (Pomeranian Medical University)H-Index: 41
view all 20 authors...
Source
#1Rebecca C. Arend (UAB: University of Alabama at Birmingham)H-Index: 16
#2Bradley J. Monk (UA: University of Arizona)H-Index: 52
Last. Marilyn HuangH-Index: 7
view all 14 authors...
Source
#2Jae Weon Kim (SNU: Seoul National University)H-Index: 44
Last. Jacob Korach (Sheba Medical Center)H-Index: 19
view all 20 authors...
Source
#1Ursula A. Matulonis (Harvard University)H-Index: 60
#2Roni Shapira (Sheba Medical Center)H-Index: 1
Last. Jalid Sehouli (FU: Free University of Berlin)H-Index: 55
view all 19 authors...
Source
#1Jonathan A. Ledermann (UCL: University College London)H-Index: 49
#2Amit M. Oza (Princess Margaret Cancer Centre)H-Index: 54
Last. Giovanni ScambiaH-Index: 77
view all 24 authors...
Summary Background In ARIEL3, rucaparib maintenance treatment significantly improved progression-free survival versus placebo. Here, we report prespecified, investigator-assessed, exploratory post-progression endpoints and updated safety data. Methods In this ongoing (enrolment complete) randomised, placebo-controlled, phase 3 trial, patients aged 18 years or older who had platinum-sensitive, high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube carcinoma and an Easter...
3 CitationsSource
#1Claire Newton (UoB: University of Bristol)H-Index: 3
#2Andy Nordin (East Kent Hospitals University Nhs Foundation Trust)H-Index: 8
Last. Andrea Fernandes (The Royal Marsden NHS Foundation Trust)H-Index: 1
view all 22 authors...
The National Cancer Survivorship Initiative through the National Health Service (NHS) improvement in the UK started the implementation of stratified pathways of patient-initiated follow-up (PIFU) across various tumor types. Now the initiative is continued through the Living With and Beyond Cancer program by NHS England. Evidence from non-randomized studies and systematic reviews does not demonstrate a survival advantage to the long-established practice of hospital-based follow-up regimens, tradi...
4 CitationsSource
#1David M. O'Malley (OSU: Ohio State University)H-Index: 38
#2Amit M. Oza (Princess Margaret Cancer Centre)H-Index: 54
Last. Giovanni ScambiaH-Index: 1
view all 25 authors...
#1Jonathan A. Ledermann (UCL: University College London)H-Index: 49
#2Nicoletta Colombo (University of Milan)H-Index: 53
Last. Myong Cheol LimH-Index: 21
view all 18 authors...
12345678910